ArticleHepatology international2008
A prospective study of antituberculous drug-induced hepatotoxicity in an area endemic for liver diseases.
Article in Hepatology international, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 82 citations in OpenAlex.
- Risk factors for drug-induced liver injury in tuberculosis patients: a meta-analysis and systematic review.Frontiers in medicine · 2026Pooled it
- Systematic review and network meta-analysis of efficacy and safety of interventions for preventing anti-tuberculosis drug induced liver injury.Scientific reports · 2023Pooled it
- Prevalence of hepatotoxicity among HIV-infected patients in Ethiopia: a systematic review and meta-analysis.BMC infectious diseases · 2022Pooled it
- A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury.BMC complementary and alternative medicine · 2015Trial
- Anti-tuberculosis drug-induced hepatotoxicity among patients undergoing tuberculosis treatment at the Antituberculosis Center of Brazzaville, Republic of Congo.IJID regions · 2026Article
- Incidence and risk factors of abnormal liver function and anti-tuberculosis drug-induced liver injury: a multicenter retrospective study involving 482 chinese pediatric tuberculosis patients.Annals of medicine · 2025Article
- Development and external validation of a pre-treatment nomogram for predicting drug-induced liver injury risk in tuberculosis patients.Scientific reports · 2025Article
- Antitubercular drug induced liver injury among tuberculosis patients in central Ethiopia.Scientific reports · 2025Article
- Incidence, Clinical Features, Associated Factors and Outcomes of Intensive Phase Antituberculosis Drug Induced Liver Injury Among Patients With Tuberculosis at a Tertiary Care Hospital in Nepal: A Descriptive Cross-Sectional Study.Health science reports · 2025Article
- Risk factors associated with post-tuberculosis sequelae: a systematic review and meta-analysis.EClinicalMedicine · 2024Article
- Polymorphisms in drug metabolism genes as a risk factor for first-line anti-tuberculosis drug-induced liver injury.Molecular biology reports · 2023Review
- Roles of Cofactors in Drug-Induced Liver Injury: Drug Metabolism and Beyond.Drug metabolism and disposition: the biological fate of chemicals · 2022Review
- Involvement of endoplasmic reticulum stress in rifampicin-induced liver injury.Frontiers in pharmacology · 2022Review
- Anti-Tuberculosis Drug Induced Hepatotoxicity and Associated Factors among Tuberculosis Patients at Selected Hospitals, Ethiopia.Hepatic medicine : evidence and research · 2021Article
- Phytochemical analysis and Evaluation of hepatoprotective effect of Maytenus royleanus leaves extract against anti-tuberculosis drug induced liver injury in mice.Lipids in health and disease · 2020Article
- Article
- N-Acetyl Cysteine as an Adjunct in the Treatment of Tuberculosis.Tuberculosis research and treatment · 2020Review
- Safety implications of combined antiretroviral and anti-tuberculosis drugs.Expert opinion on drug safety · 2020Review
- Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross-disease cohort study.Alimentary pharmacology & therapeutics · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIdentification of risk factors associated with antituberculosis drug-induced hepatotoxicity (anti-TB-DIH) is important, especially in endemic area for TB and liver disease. This study assessed the incidence and risk factors of anti-TB-DIH in upper Egyptian patients treated for active pulmonary and extra-pulmonary TB.
methodsA total of 100 consecutive TB patients were prospectively followed up both clinically and biochemically before and during their course of anti-TB therapy with daily doses of isoniazid, rifampin, ethambutol, and pyrazinamide, or streptomycin.
resultsAnti-TB-DIH developed in 15 (15%) patients within 15-60 days (median: 30 days) from the onset of therapy. Liver function normalized in 10 (60%) patients within 2 weeks from cessation of therapy. No recurrence of DIH was observed after reintroduction of therapy. Only 1 patient died from fulminant hepatic failure despite discontinuation of all anti-TB drugs. By univariate analysis, patients with anti-TB-DIH had more pre-existing liver disease (P = 0.024; OR: 3.60; 95% CI: 1.16-11.18), lower body mass index (BMI; P = 0.037; OR: 3.73; 95% CI: 1.04-10.56), lower serum albumin (P = 0.035; OR: 3.31; 95% CI: 1.04-10.56), and more extensive disease (P = 0.033; OR: 3.50; 95% CI: 1.11-11). Age, gender, raised baseline transaminases level, inclusion of pyrazinamide, and inactive hepatitis B or C carrier state were not significant risk factors of DIH. Using multivariate regression analysis, only pre-existing liver disease and lower BMI of 20 kg/m(2) or less were independent predictors of DIH (P = 0.024 and P = 0.047, respectively).
conclusionAnti-TB-DIH is not uncommon, needs early recognition and treatment, and is more in patients with pre-existing liver disease and low BMI.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.